Zhifei Biological returns to profit in the third quarter as clearance of near-expiry vaccines is completed and margins recover
Third-quarter revenue and net profit both exceeded Goldman Sachs' expectations, but revenue still fell 7% year on year. Goldman Sachs believes destocking is largely complete and has raised its target price to 19 yuan.
Goldman Sachs ·